Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07526194
PHASE1
A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are Tolerated
Sponsor: Boehringer Ingelheim
View on ClinicalTrials.gov
Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3821001 in healthy male trial participants.
Official title: A Phase I Single-blind, Randomised, Placebo-controlled, Parallel Group Design Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BI 3821001 Administered to Healthy Trial Participants
Key Details
Gender
MALE
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2026-04-22
Completion Date
2026-10-02
Last Updated
2026-04-13
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
BI 3821001
BI 3821001
DRUG
Placebo
Placebo
Locations (1)
CRS Clinical Research Services Berlin GmbH
Berlin, Germany